This is a working overview of angiotensin IV, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-02. Anything still debated is marked as such rather than presented as settled.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
== Epidemiology == As of December 2023, most people who acquire this disease are between the ages of two and six years old, living in the poorest countries of the world. Accurate figures for noma prevalence are not available due to difficulties in diagnosis and reporting in the endemic areas. In 1998, the World Health Organization estimated that 140,000 new cases were occurring each year, with a 90% fatality rate, and a total of 770,000 surviving with scarring or disfigurement. Noma is associated with a very high morbidity, and a mortality rate of approximately 90 percent. The prognosis is much better with treatment; if children have access to medical care, the mortality rate drops to under 10 percent. After gangrene sets in, patients are likely to die of sepsis within one to two weeks.
Laurin Weissinger argued that it is important for such software to be fully free and open source, to clarify concepts and designs, to have it tested by security experts and to describe data that is collected and how it is used to build trust. Jenny Wanger contended that it is essential for such software to be open source. Jay Stanley affirmed this notion and warned that an "architecture that is not good for transparency, privacy, or user control" could set a "bad standard" for future credentialing systems.
=== Higher-calorie variants === In extreme cold temperatures, the packaged wet food in MREs can freeze solid, rendering the food inedible and the heating packet insufficient. The Meal, Cold Weather (MCW) provides a ration similar to the MRE designed for lower temperatures than the MRE can withstand. Clad in white packaging, it offers a freeze-dried entree designed to be eaten with heated water, the same side ingredients as the standard MRE, and additional drink mixes to encourage additional hydration. The caloric and fat content of the meals is also increased. The MCW replaced the Ration, Cold Weather (RCW). The Meal, Long Range Patrol (LRP) is essentially the same as the MCW, but with different accessory packs. The MLRP is designed for troops who may receive limited or no supply, and weight of the ration is critical. The similar First Strike Ration is along the same lines, but requires no preparation and may be eaten on the go.
===== MeSH D08.811.913.200 – aldehyde-ketone transferases (EC 2.2) ===== MeSH D08.811.913.200.324 – acetolactate synthase MeSH D08.811.913.200.650 – transaldolase MeSH D08.811.913.200.825 – transketolase
Sources: en.wikipedia.org
As treasurer, Kennedy sought to refinance portions of Louisiana's debt from Hurricanes Katrina and Rita as interest rates decreased. He worked with the state legislature and several governors' offices to negotiate each refinancing. In 2004, Kennedy told the state legislature that he could save more than $1.4 billion by refinancing the state's debt. He noted that he had sent Governor Kathleen Blanco several letters about refinancing that went unanswered. In 2011, Kennedy announced that Lafayette and Livingston Parishes had saved $11 million by refinancing. By 2013, Kennedy said he had "refinanced virtually all of the state's debt". In 2014, Kennedy worked to refinance $229 million in bond debt. The project faced delays because of a disagreement with Governor Bobby Jindal's office over accounting practices. Jindal's team claimed Kennedy was "unnecessarily holding up" progress on many construction projects, but Kennedy maintained that Jindal's accounting practices potentially violated federal anti-fraud laws. The two sides eventually compromised and the deal moved ahead, saving Louisiana $12 million. By the end of 2014, Kennedy had saved Louisiana a total of more than $600 million by refinancing debt. In 2015, Kennedy saved Louisiana $109 million over 26 years by refinancing a $649 million loan that funded a highway project.
== Modern Development: Sector 13 == For decades, Manimajra sat outside Chandigarh's formal grid because the city's planner, Le Corbusier, omitted the number 13 due to superstition. Following long-standing demands from residents in upscale enclaves like the Modern Housing Complex (MHC) and Shivalik Enclave, the area was officially integrated into the sectoral grid as Sector 13 in February 2020. This change was enacted by Governor V.P. Singh Badnore under the Capital of Punjab Act of 1952.
=== Shang dynasty === Traces of therapeutic activities in China date from the Shang dynasty (14th–11th centuries BCE). Though the Shang did not have a concept of "medicine" as distinct from other health practices, their oracular inscriptions on bones and tortoise shells refer to illnesses that affected the Shang royal family: eye disorders, toothaches, bloated abdomen, and such. Shang elites usually attributed them to curses sent by their ancestors. There is currently no evidence that the Shang nobility used herbal remedies. Stone and bone needles found in ancient tombs led Joseph Needham to speculate that acupuncture might have been carried out in the Shang dynasty. This being said, most historians now make a distinction between medical lancing (or bloodletting) and acupuncture in the narrower sense of using metal needles to attempt to treat illnesses by stimulating points along circulation channels ("meridians") in accordance with beliefs related to the circulation of "Qi". The earliest evidence for acupuncture in this sense dates to the second or first century BCE.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.